BioXcel Therapeutics Announces Extension of FDA Review Period of its NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy